do glp 1 cause elevated liver enzymes Xia & He Publishing Glucagon-like peptide-1 receptor agonists improve

The hidden costs of silencing hunger with GLP-1s like Wegovy and Ozempic.

One of the most exciting

pathway therapeutic paradox

The 2nd GLP-1-Based Therapeutics Summit returns to tackle the challenges in best-in-class GLP-1 development and indication expansion with new clinical data, new preclinical data, and 18+ expert speakers including Eli Lily, Regeneron, Roche, Novo Nordisk, Fractyl Health and more at the forefront of the field

Nuestro compromiso incluye

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk